8-K: Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Reports Year-End Financials

Milestone Pharmaceuticals announces its Q4 and full-year 2024 financial results while awaiting the FDA's decision on CARDAMYST for PSVT, with a potential launch targeted for mid-2025.

Summary

• Milestone Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is awaiting FDA approval for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT), with a PDUFA review goal date of March 27, 2025.
• Assuming FDA approval, the proposed launch of CARDAMYST is targeted for mid-2025.
• As of December 31, 2024, Milestone had $69.7 million in cash, cash equivalents, and short-term investments, compared to $66.0 million on December 31, 2023.
• There was no revenue recorded for the fourth quarter or full year ended December 31, 2024, compared to $1.0 million in the year ended December 31, 2023.
• Research and development expense for the full year ended December 31, 2024, was $14.4 million, compared with $31.1 million for the prior year.
• General and administrative expense for the full year ended December 31, 2024, was $16.7 million, compared with $15.9 million for the prior year.
• Commercial expense for the full year ended December 31, 2024, was $11.0 million, compared with $15.1 million for the prior year.
• Milestone's net loss for the full year ended December 31, 2024, was $41.5 million or $0.67 per share, compared to a net loss of $59.7 million or $1.39 per share for the prior year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the anticipation of FDA approval for CARDAMYST, the potential launch in mid-2025, and the extension of intellectual property protection; however, the lack of current revenue and ongoing net losses temper the overall sentiment.

Positives

• Milestone is well-capitalized to commercialize CARDAMYST upon approval with royalty financing.
• The company received a Notice of Allowance from the USPTO for a new Method of Use patent, potentially extending intellectual property protection until July 2042.
• Milestone is progressing with plans to initiate a Phase 3 trial for etripamil in AFib-RVR in 2025.
• The company's cash position remains strong at $69.7 million as of December 31, 2024.
• The net loss decreased from $59.7 million in 2023 to $41.5 million in 2024.

Negatives

• Milestone recorded no revenue for the fourth quarter or full year ended December 31, 2024.
• The company reported a net loss of $41.5 million for the full year ended December 31, 2024.

Risks

• The FDA may not approve CARDAMYST for PSVT.
• Clinical trials may not validate the safety and efficacy of etripamil for PSVT or other indications.
• General economic, political, and market conditions could negatively impact the company.
• The company's ability to raise additional capital in the current economic climate is a risk.

Future Outlook

Milestone is focused on the potential FDA approval for CARDAMYST and the opportunity to help patients suffering from PSVT, with launch preparations underway and resources secured for a mid-year launch, assuming FDA approval; the company is also on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025.

Management Comments

• 'We are focused on the potential FDA approval for CARDAMYST and the opportunity to help the millions of patients suffering from PSVT,' said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals.
• Management stated that launch preparations are well underway and resources are secured to make CARDAMYST available to patients and healthcare providers mid-year, assuming FDA approval.

Industry Context

Milestone Pharmaceuticals is developing a novel treatment option for PSVT and AFib-RVR, conditions that affect millions of patients; the successful development and commercialization of CARDAMYST could provide a significant advancement in the management of these conditions, offering patients a self-administered rapid response therapy.

Comparison to Industry Standards

• Etripamil, as a self-administered nasal spray, aims to provide a more convenient and rapid treatment option compared to traditional antiarrhythmic drugs that often require medical supervision for administration.
• Companies like BioMarin Pharmaceutical Inc. and Vertex Pharmaceuticals Incorporated are known for developing innovative therapies for specific patient populations, a strategy Milestone is also pursuing with CARDAMYST.
• The potential extension of intellectual property protection for CARDAMYST until 2042 is a significant advantage, similar to how companies like AbbVie protect their key assets like Humira through patents and exclusivity periods.
• Milestone's focus on patient self-management aligns with the broader industry trend towards personalized medicine and empowering patients to take control of their health.

Stakeholder Impact

• Shareholders: The potential FDA approval and commercialization of CARDAMYST could positively impact shareholder value.
• Patients: If approved, CARDAMYST could provide a new treatment option for patients with PSVT, enabling on-demand care and patient self-management.
• Healthcare Providers: CARDAMYST could offer healthcare providers a new tool for managing PSVT and AFib-RVR.
• Employees: The company's success depends on the continued efforts of its employees in developing and commercializing CARDAMYST.

Next Steps

• Awaiting FDA decision on CARDAMYST by the PDUFA review goal date of March 27, 2025.
• Preparing for the potential commercial launch of CARDAMYST in mid-2025, assuming FDA approval.
• Initiating a Phase 3 trial evaluating etripamil in AFib-RVR in 2025.
• Presenting a poster on Etripamil at the American College of Cardiology Annual Meeting (ACC.25) on March 30, 2025.

Key Dates